Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. EU, Zimmer agree to extend review of Biomet merger
Zimmer said it agreed with the European Commission to extend an anti-trust review of its pending merger with Biomet “by a limited number of days.”
EuroZone regulators are looking at the proposed merger, which would see Zimmer pay $13.35 billion for Biomet, over concerns that the creation of the world’s 2nd-largest orthopedic products group may hurt competition. Both companies are based in Warsaw, Ind. Read more
2. Medtronic’s Q2 results meet The Street
Medtronic today reported 2nd-quarter results that met expectations on Wall Street.
The Fridley, Minn.-based medical device giant posted profits of $828 million, or 83¢ per share, on sales of $4.37 billion for the 3 months ended Oct. 24. Adjusted to exclude 1-time items, earnings per share were 96¢, in line with expectations on Wall Street, where analysts were also looking for revenues of $4.37 billion. Read more
1. DaVita, Medtronic to study arrhythmia in dialysis patients
Medtronic and dialysis provider DaVita Healthcare Partners said they plan to team up to identify and study cardiac arrhythmia in patients undergoing dialysis.
The announcement comes on the heels of a Medtronic study showing a higher incidence of arrhythmias in certain hemodialysis patients. Read more